INTRODUCTION
============

Gastric neoplasms, including gastric adenoma (GA) and early gastric cancer (EGC), are among the most common neoplasms worldwide. Endoscopic submucosal dissection (ESD) is the preferred treatment for GA and EGC due to its low recurrence rate and high complete resection rate for gastric neoplasms.[@b1-gnl-08-480]--[@b3-gnl-08-480] However, several complications of ESD, such as perforation, bleeding, prepyloric or pyloric stenosis, transient bacteremia, and aspiration pneumonia, have been reported in several previous studies and were attributed to its technical difficulties and invasiveness.[@b4-gnl-08-480]--[@b7-gnl-08-480]

The most common concern for patients after gastric ESD is delayed bleeding. Delayed bleeding has been reported to occur in approximately 5% to 15% of artificial ulcers, which are disruptions in the mucosal integrity of the stomach after ESD.[@b4-gnl-08-480]--[@b6-gnl-08-480] Fortunately, most delayed bleeding cases are controlled by appropriate emergency endoscopic treatment, although a surgery is required as part of the treatment in some cases.

Several previous studies have reported that second-look endoscopy (SLE) prevents further bleeding after endoscopic treatment for peptic ulcer bleeding in the stomach.[@b8-gnl-08-480]--[@b10-gnl-08-480] A significant number of authors recommend performing SLE for artificial ulcers, especially for lesions with significant risk factors for delayed bleeding, including tumor location,[@b11-gnl-08-480] tumor size,[@b5-gnl-08-480],[@b12-gnl-08-480],[@b13-gnl-08-480] specimen size,[@b5-gnl-08-480],[@b14-gnl-08-480] and ulcerative findings.[@b12-gnl-08-480] However, artificial ulcers after ESD are exposed to relatively high pH conditions in comparison with peptic ulcers. Lately, a retrospective study reported that SLE might not be necessary for avoiding delayed bleeding.[@b4-gnl-08-480] By contrast, another retrospective study suggested the use of SLE could prevent delayed bleeding, especially in high-risk gastric lesions.[@b14-gnl-08-480] Therefore, we conducted a prospective, randomized, single-blind, controlled trial to investigate whether SLE prevents delayed bleeding and is necessary after ESD and to validate the predictive factors of delayed bleeding.

MATERIALS AND METHODS
=====================

1. Patients and materials
-------------------------

A total of 446 lesions histologically diagnosed as gastric neoplasms and consecutively treated with ESD at Chonnam National University Hwasun Hospital, Hwasun, Korea from January 2012 to May 2013 were enrolled. The Ethical Committee of the Chonnam National University Medical School approved the study (clinical trial number: CNUHH-2012--20), which was conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients included in the study signed a written informed consent prior to inclusion.

2. Inclusion criteria and exclusion criteria
--------------------------------------------

In the study, all patients who visited our hospital to receive ESD treatment for gastric neoplasms were included. ESD was principally indicated for GAs and EGCs corresponding to the expanded criteria suggested by Gotoda *et al*.[@b15-gnl-08-480] as based on endoscopic findings, including chromoendoscopy, narrow band imaging, biopsy, and abdominal computed tomography. Exclusion criteria were as follows: pregnancy; breast feeding; bleeding on resected lesions within 24 hours after ESD; taking gastric mucosal protectors, acid suppressants, anticoagulants, and/or antiplatelets within 1 week of the ESD; known allergies to proton pump inhibitors (PPIs); mental and/or physical disabilities; and refusal to consent to participate in the study.

3. Study design
---------------

The study design was a prospective, randomized, single-blind, controlled trial, as shown in [Fig. 1](#f1-gnl-08-480){ref-type="fig"}. All patients included in the study were assigned randomly using sealed, numbered envelopes to either a non-SLE group or a SLE group that received SLE on the morning of the second postoperative day (POD), as shown in [Fig. 2](#f2-gnl-08-480){ref-type="fig"}. The randomization number was not exposed to the endoscopist until the study completion date. The endoscopist was instructed not to ask other doctors or patients whether the patients had received SLE. The patients ate only a liquid diet at admission day. Patients fasted from midnight at admission day until noon of POD 2. Based on a standard protocol,[@b16-gnl-08-480],[@b17-gnl-08-480] the ESDs were performed for the patients under conscious sedation on Tuesday and Wednesday. The operator was a single experienced endoscopist (S.B. Cho) who had performed ESD over 500 times for more than 5 years. The normal mucosa located more than 5 mm away from the tumor margin was marked using an argon plasma coagulator (VIO 300D; Erbe Elektromedizin, Tübingen, Germany). Epinephrine mixed with hypertonic saline (1:100,000) containing 1% indigo carmine was injected into the submucosal layer to raise the lesion. Hyaluronic acid was used if the tumor was insufficiently elevated. A circumferential mucosa was cut around the marks. Subsequently, the submucosal layer, including the tumor, was dissected using an insulation-tipped diathermic knife (KD-611L; Olympus, Tokyo, Korea) or dual knife (KD-650; Olympus). We used hemostatic forceps (FD-410LR; Olympus) and hemostatic clips (HX-610-135 or HX-610-090L; Olympus) for bleeding and for all exposed vessels on the resected lesion during ESD. Additionally, all the lesions underwent prophylactic coagulation for nonbleeding exposed vessels on resected lesions after the removal of lesions on the stomach.[@b11-gnl-08-480]

SLE was performed to inspect the artificial ulcer on the morning of POD 2 to evaluate whether there was recent bleeding or the possibility of bleeding lesions (nonbleeding visible vessels and adherent clots). Three days after ESD, pantoprazole (Pantoloc injection; Takeda Pharm Co., Osaka, Japan) at 40 mg per day or lansoprazole (Lanston injection; Takeda Pharm Co.) at 40 mg per day was administered intravenously and continuously. After POD 3, patients took orally 40 mg of pantoprazole (Pantoloc^®^; Takeda Pharm Co.) or 30 mg of lansoprazole (Lanston^®^; Takeda Pharm Co.) once daily for the following 54 days. All patients resumed food intake when the afternoon had passed on POD 2 and were discharged at POD 4 unless there were any of signs of complications, such as hematemesis, hematochezia, melena, fever, or abdominal pain. All participants were instructed to contact our hospitals when experiencing these signs of complications after discharge, and were asked to visit the outpatient clinic at 2 and 8 weeks after ESD. Based on the healing process of the artificial ulcer, the follow-up period was 56 days.[@b18-gnl-08-480] If the patient had 2 or more gastric neoplasms, we treated each gastric neoplasm at intervals of about 3 months.

If the patient showed any bleeding signs or symptoms after ESD, we performed emergency endoscopy to check whether any of the lesions required endoscopic hemostasis, such as for bleeding or possibly bleeding lesions, and treated these lesions with a hemostatic clip and/or thermocoagulator. We prescribed blood transfusion only for patients with bleeding artificial ulcers and decreases in hemoglobin levels \>2 g/dL.

4. Data analysis
----------------

Delayed bleeding was defined as massive bleeding at 1 to 56 days after ESD and as requiring emergency endoscopic hemostasis for endoscopically evident bleeding sites on resected lesions because of hematemesis, melena, hematochezia. *En bloc* resection was defined as resection in a single piece with negative lateral and vertical margins. A long procedure time was defined as a procedure time (from passing the endoscopy through the mouth to complete withdrawal) of more than 60 minutes. The longitudinal parts of the stomach were equally divided into the upper, middle, and lower portions. The circumferential parts of the stomach were equally separated into four portions: the anterior wall, posterior wall, greater curvature, and lesser curvature. A large tumor size was defined as one greater than 20 mm. All tumors were divided into three histologic types based on the Vienna classification:[@b19-gnl-08-480] low-grade dysplasia, high-grade dysplasia, and EGC. The macroscopic types, differentiation, depth of invasion, and lymphovascular invasion of the gastric neoplasms were classified according to the Japanese Gastric Cancer Association classification.[@b20-gnl-08-480]

The following variables were analyzed to demonstrate predictive factors for delayed bleeding: age, sex, body mass index, laboratory findings on admission (white blood count, hemoglobin, platelet, prothrombin time, and activated partial thromboplastin time), history of stomach operation, history of gastric ESD, the use of anticoagulants and/or antiplatelet drugs 1 week before the procedure, tumor location (longitudinal and circumferential), gross tumor type (elevated, flat, or depressed), endoscopic ulcerative findings, the presence of fibrosis in the submucosal layer during ESD, the resection type (*en bloc* or piecemeal), resected specimen size (largest diameter), tumor size (largest diameter), depth of cancer (epithelium, lamina propria, muscularis mucosae, or submucosa), histologic type, infection by *Helicobacter pylori*, PPI type, and ESD procedure time. In addition, we evaluated the incidence of delayed bleeding and the frequencies of various risk factors for delayed bleeding between the SLE and non-SLE groups to investigate whether SLE prevented delayed bleeding.

5. Statistical analysis
-----------------------

The SPSS software version 18.0 (IBM Co., Armonk, NY, USA) was used to perform the statistical analysis. All values are expressed as the means±SD and were analyzed by the Student t-test. The categorical variables were analyzed by the chi-square test or Fisher exact test. A value of p\<0.05 was accepted as statistical significance. If more than one of these factors was significant in the univariate analysis, a multiple logistic regression analysis was performed to identify an independent factor.

RESULTS
=======

Of the 446 lesions with gastric neoplasms in this study, *en bloc* resections were performed in 435 lesions (97.5%). All the tumor lesions had tumor-free margins histologically. Only one case was managed with surgery due to lymphovascular invasion. No perforations after ESD and no deaths related to ESD and/or the subsequent surgery were observed. Bleeding occurred within 24 hours after ESD for five of the resected lesions; these cases were consequently excluded from the study. Delayed bleeding occurred in 18 (4.1%) of 441 lesions and was successfully controlled by emergency endoscopic treatment. According to the Forrest classification,[@b21-gnl-08-480] these cases were classified into four categories: spurting bleeding (four cases), oozing bleeding (six cases), nonbleeding visible vessels (six cases), and adherent clots (two cases). Blood transfusions were performed in five of the 18 delayed bleeding cases. No additional cases of delayed bleeding were observed after the endoscopic treatment.

We investigated the 441 lesions to validate various risk factors for delayed bleeding. Univariate analysis indicated a long procedure time (odds ratio \[OR\], 3.77; 95% confidence interval \[CI\], 1.44 to 9.88; p=0.004) and large tumor size (OR, 6.27; 95% CI, 2.30 to 17.09; p\<0.001) were significantly associated with delayed bleeding, as shown in [Table 1](#t1-gnl-08-480){ref-type="table"}. Multivariate logistic regression analysis showed that large tumor size was the only independent risk factor related to late delayed bleeding (p=0.007), as shown in [Table 2](#t2-gnl-08-480){ref-type="table"}.

Delayed bleeding occurred in four lesions within 48 hours after ESD. Hence, we enrolled the remaining 437 lesions to determine the utility of SLE for delayed bleeding. [Table 3](#t3-gnl-08-480){ref-type="table"} shows the incidence of risk factors for delayed bleeding and the frequencies of delayed bleeding between the SLE and non-SLE groups. SLE was performed on 220 lesions on the morning of POD 2. The chance of delayed bleeding was not significantly different between the SLE (eight cases) and non-SLE (six cases) groups (p=0.787). Moreover, no significant differences were observed in the risk factors for delayed bleeding between the SLE and non-SLE groups. Thirty five lesions were treated with prophylactic hemostasis using hemostatic clips for nonbleeding visible vessels after the removal of adherent clots. Three cases (8.6%) in the SLE group showed delayed bleeding after prophylactic endoscopic treatment.

DISCUSSION
==========

According to Takizawa *et al*.,[@b11-gnl-08-480] the subsequent coagulation of nonbleeding visible vessels in lesions resected by ESD significantly prevented delayed bleeding in most but not all cases. This prevention of delayed bleeding is the reason why most hospitals routinely perform SLE after ESD. Contrary to expectations, the incidence of delayed bleedings between the SLE and non-SLE groups was not significantly different in our study. Additionally, the incidence of delayed bleeding with prophylactic endoscopic hemostasis was higher than that without prophylactic endoscopic hemostasis, although this trend was not statistically significant (p=0.093). Given these findings, we suggest that SLE has limited value, if any, for reducing the incidence of delayed bleeding, and that the treatment of prophylactic hemostasis for adherent clots may be an unnecessary or immoderate procedure. These findings from our study are consistent with those of a previous report, which found that endoscopic treatment may result in rebleeding because new blood vessels can arise from a lesion treated through endoscopic hemostasis.[@b4-gnl-08-480] As well, another previous study noted the natural healing reactions of artificial ulcers might be one of the major contributors in preventing delayed bleeding.[@b14-gnl-08-480]

As shown by a univariate analysis, a long procedure time and a large tumor size were risk factors for delayed bleeding in the present study. In the multivariate analysis, a large tumor size was the only independent predictive factor for delayed bleeding. These results suggested the procedure time was positively related with tumor size, and are in keeping with the findings of previous reports.[@b5-gnl-08-480],[@b22-gnl-08-480] Further, several retrospective studies have reported that a large tumor size was a significant factor for delayed bleeding.[@b5-gnl-08-480],[@b12-gnl-08-480],[@b13-gnl-08-480] The current prospective study showed that SLE for lesions with risk factors for delayed bleeding did not significantly reduce the incidence of delayed bleeding, suggesting SLE has little or no influence on the prevention of delayed bleeding, irrespective of the risk factor for it.

Previous reports have shown that specimen size is a significant predictive factor for delayed bleeding.[@b5-gnl-08-480],[@b14-gnl-08-480] The present study revealed that tumor size rather than lesion size was a significant risk factor for delayed bleeding. In general, specimen size is directly proportional to tumor size. We believe the reason as to why tumor size is the only predictive factor for delayed bleeding might be the relatively inaccurate ESD procedure.

Because *H. pylori* infection is one of factors influencing the healing of gastric ulcers,[@b23-gnl-08-480] we performed Campylobacter-like organism (Asan Pharm Co., Ltd., Hwasung, Korea) tests for the diagnosis of *H. pylori* for all patients and evaluated whether this bacterium affected the rate of delayed bleeding. In accordance with previous reports,[@b6-gnl-08-480],[@b24-gnl-08-480] the present study did not find any significant correlations between *H. pylori* status and the delayed bleeding rate.

In our cases, the incidence of complications after ESD, such as perforations, delayed bleeding, and positive lymphovascular invasion, was lower than that of previous studies.[@b4-gnl-08-480]--[@b6-gnl-08-480] Several possible reasons could explain these results. First, recent improvements in the therapeutic modalities and techniques have led to a decrease in the incidence of complications for gastric neoplasms. Second, none of the ESD lesions had positive/intermediate lateral margins. Recently, Nakamura *et al*.[@b6-gnl-08-480] suggested that a positive/intermediate lateral margin was a significant risk factor for delayed bleeding. Third, the tumor size (mean±SD, 10.4±7.3 mm) in the present study was relatively smaller than those in other studies.[@b4-gnl-08-480]--[@b6-gnl-08-480]

The current study had at least two limitations. First, the study was a relatively small single-center one. Second, the study did not evaluate the different cytochrome P450 2C19 (CYP2C19) genotypes of each individual. These genotypes can influence the metabolism of PPIs and thereby might be related to the healing rate of artificial ulcers after ESD.[@b25-gnl-08-480] For these reasons, a large prospective, multicenter, randomized control trial evaluating the differences between CYP2C19 genotypes is required to provide more definitive evidence.

In conclusion, based on our prospective study, a large tumor size is an independent risk factor for delayed bleeding. However, SLE has little or no influence on the prevention of delayed bleeding, irrespective of the risk factor for it.

See editorial on page 459.
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![The study design.\
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###### 

A Univariate Analysis of the Risk Factors for Delayed Bleeding

  Characteristic                            Delayed bleeding   p-value         
  ----------------------------------------- ------------------ --------------- ---------------------------------------------------
  Age, yr                                   67.1±7.5           65.8±9.6        0.570[\*](#tfn3-gnl-08-480){ref-type="table-fn"}
  Sex, male/female                          14/4               277/146         0.323[†](#tfn4-gnl-08-480){ref-type="table-fn"}
  Body mass index, kg/m^2^                  23.1±2.2           24.0±3.0        0.233[\*](#tfn3-gnl-08-480){ref-type="table-fn"}
  Platelet, ×1,000                          213.1±68.0         229.4±55.1      0.223[\*](#tfn3-gnl-08-480){ref-type="table-fn"}
  Hgb                                       13.5±1.9           13.9±2.2        0.499[\*](#tfn3-gnl-08-480){ref-type="table-fn"}
  PT, sec                                   12.6±0.9           12.5±0.8        0.434[\*](#tfn3-gnl-08-480){ref-type="table-fn"}
  aPTT                                      35.4±2.2           35.2±3.0        0.790[\*](#tfn3-gnl-08-480){ref-type="table-fn"}
  Anticoagulants/Antiplatelets              3                  37              0.218[†](#tfn4-gnl-08-480){ref-type="table-fn"}
  Previous history of ESD                   2                  24              0.287[†](#tfn4-gnl-08-480){ref-type="table-fn"}
  History of stomach operation              1                  10              0.371[†](#tfn4-gnl-08-480){ref-type="table-fn"}
  Underlying disease                                                           
   Hypertension                             4                  174             0.142[†](#tfn4-gnl-08-480){ref-type="table-fn"}
   Diabetes mellitus                        2                  76              0.752[†](#tfn4-gnl-08-480){ref-type="table-fn"}
   Cerebrovascular accident                 1                  5               0.222[†](#tfn4-gnl-08-480){ref-type="table-fn"}
   Ischemic heart disease                   1                  6               0.255[†](#tfn4-gnl-08-480){ref-type="table-fn"}
   Liver cirrhosis                          1                  10              0.371[†](#tfn4-gnl-08-480){ref-type="table-fn"}
   Chronic renal failure                    2                  24              0.287[†](#tfn4-gnl-08-480){ref-type="table-fn"}
  Type of PPI, pantoprazole/lansoprazole    10/8               203/220         0.633[†](#tfn4-gnl-08-480){ref-type="table-fn"}
  Size of specimen, mm                      44.8±12.2          39.9±11.0       0.068[\*](#tfn3-gnl-08-480){ref-type="table-fn"}
  Long procedure time, \>60 min             8                  74              0.004[‡](#tfn5-gnl-08-480){ref-type="table-fn"}
  Location of lesion                                                           
   Longitudinal, U/M/L                      2/3/13             23/88/312       0.603[‡](#tfn5-gnl-08-480){ref-type="table-fn"}
   Circumferential, AW/PW/LC/GC             3/3/9/3            95/78/127/123   0.327[‡](#tfn5-gnl-08-480){ref-type="table-fn"}
  Type of lesion, elevated/flat/depressed   10/4/4             219/54/150      0.972[‡](#tfn5-gnl-08-480){ref-type="table-fn"}
  Ulcerative finding                        4                  42              0.106[†](#tfn4-gnl-08-480){ref-type="table-fn"}
  Resection style, piecemeal/*en bloc*      1/17               10/413          0.371[†](#tfn4-gnl-08-480){ref-type="table-fn"}
  Fibrosis in submucosa                     6                  79              0.131[†](#tfn4-gnl-08-480){ref-type="table-fn"}
  Large tumor size, \>20 mm                 7                  39              \<0.001[‡](#tfn5-gnl-08-480){ref-type="table-fn"}
  Histologic type, LGD/HGD/cancer           7/3/8              202/52/169      0.552[‡](#tfn5-gnl-08-480){ref-type="table-fn"}
  Depth of cancer, E/LP/MM/S                0/5/3/0            7/108/48/6      0.779[‡](#tfn5-gnl-08-480){ref-type="table-fn"}
  *H. pylori* infection                     15                 366             0.723[†](#tfn4-gnl-08-480){ref-type="table-fn"}

Data are presented as mean±SD or number.

Hgb, hemoglobin; PT, prothrombin time; aPTT, activated partial thromboplastin time; ESD, endoscopic submucosal dissection; PPI, proton pump inhibitor; U, upper; M, middle; L, lower; AW, anterior wall; PW, posterior wall; LC, lesser curvature; GC, greater curvature; LGD, low grade dysplasia; HGD, high grade dysplasia; E, epithelium; LP, lamina propria; MM, muscularis mucosae; S, submucosa; *H. pylori*, *Helicobacter pylori*.

Unpaired t-test;

Fisher exact test;

Chi-square test.

###### 

A Multivariate Analysis of the Factors Associated with Delayed Bleeding

  Factor                          Multivariate analysis                 
  ------------------------------- ----------------------- ------------- -------
  Long procedure time, \>60 min   2.38                    0.83--6.87    0.108
  Large tumor size, \>20 mm       4.47                    1.50--13.34   0.007

OR, odds ratio; CI, confidence interval.

###### 

Comparisons between the Second-Look Endoscopy (SLE) and Non-SLE Groups

  Characteristic                            SLE (n=220)   Non-SLE (n=217)   p-value
  ----------------------------------------- ------------- ----------------- --------------------------------------------------
  Age, yr                                   65.9±9.3      67.1±7.5          0.934[\*](#tfn9-gnl-08-480){ref-type="table-fn"}
  Sex, male/female                          145/75        142/75            0.920[†](#tfn10-gnl-08-480){ref-type="table-fn"}
  Body mass index, kg/m^2^                  24.0±2.8      23.9±3.2          0.793[\*](#tfn9-gnl-08-480){ref-type="table-fn"}
  Platelet, ×1,000                          228.9±47.5    228.7±63.4        0.974[\*](#tfn9-gnl-08-480){ref-type="table-fn"}
  Hgb                                       13.9±2.7      13.8±1.4          0.862[\*](#tfn9-gnl-08-480){ref-type="table-fn"}
  PT, sec                                   12.5±0.7      12.5±0.8          0.894[\*](#tfn9-gnl-08-480){ref-type="table-fn"}
  aPTT                                      35.0±2.8      35.5±3.2          0.125[\*](#tfn9-gnl-08-480){ref-type="table-fn"}
  Anticoagulants/Antiplatelets              15            24                0.133[†](#tfn10-gnl-08-480){ref-type="table-fn"}
  Previous history of ESD                   13            13                1.000[†](#tfn10-gnl-08-480){ref-type="table-fn"}
  History of stomach operation              5             6                 0.770[†](#tfn10-gnl-08-480){ref-type="table-fn"}
  Underlying disease                                                        
   Hypertension                             91            87                0.846[†](#tfn10-gnl-08-480){ref-type="table-fn"}
   Diabetes mellitus                        43            34                0.316[†](#tfn10-gnl-08-480){ref-type="table-fn"}
   Cerebrovascular accident                 2             4                 0.447[†](#tfn10-gnl-08-480){ref-type="table-fn"}
   Ischemic heart disease                   2             5                 0.282[†](#tfn10-gnl-08-480){ref-type="table-fn"}
   Liver cirrhosis                          5             6                 0.770[†](#tfn10-gnl-08-480){ref-type="table-fn"}
   Chronic renal failure                    13            13                1.000[†](#tfn10-gnl-08-480){ref-type="table-fn"}
  Type of PPI, pantoprazole/lansoprazole    107/113       104/113           0.924[†](#tfn10-gnl-08-480){ref-type="table-fn"}
  Size of specimen, mm                      40.4±11.4     39.6±10.7         0.449[\*](#tfn9-gnl-08-480){ref-type="table-fn"}
  Long procedure time, \>60 min             45            35                0.267[†](#tfn10-gnl-08-480){ref-type="table-fn"}
  Location of lesion                                                        
   Longitudinal, U/M/L                      11/41/168     13/50/154         0.243[‡](#tfn11-gnl-08-480){ref-type="table-fn"}
   Circumferential, AW/PW/LC/GC             50/43/67/60   48/38/66/65       0.579[‡](#tfn11-gnl-08-480){ref-type="table-fn"}
  Type of lesion, elevated/flat/depressed   114/29/77     112/28/77         0.938[‡](#tfn11-gnl-08-480){ref-type="table-fn"}
  Ulcerative finding                        26            20                0.437[†](#tfn10-gnl-08-480){ref-type="table-fn"}
  Resection style, piecemeal/*en bloc*      6/214         4/213             0.751[‡](#tfn11-gnl-08-480){ref-type="table-fn"}
  Fibrosis in submucosa                     41            43                0.809[†](#tfn10-gnl-08-480){ref-type="table-fn"}
  Large tumor size, \>20 mm                 24            21                0.754[†](#tfn10-gnl-08-480){ref-type="table-fn"}
  Histologic type, LGD/HGD/cancer           110/27/83     97/26/94          0.224[‡](#tfn11-gnl-08-480){ref-type="table-fn"}
  Depth of cancer, E/LP/MM/S                4/49/27/3     3/64/24/3         0.495[‡](#tfn11-gnl-08-480){ref-type="table-fn"}
  *H. pylori* infection                     193           184               0.406[†](#tfn10-gnl-08-480){ref-type="table-fn"}
  Delayed bleeding                          8             6                 0.787[†](#tfn10-gnl-08-480){ref-type="table-fn"}
   With long procedure time                 3/45          3/35              1.000[†](#tfn10-gnl-08-480){ref-type="table-fn"}
   With large tumor size                    4/24          2/21              0.670[†](#tfn10-gnl-08-480){ref-type="table-fn"}

Data are presented as mean±SD or number.

SLE, second-look endoscopy; Hgb, hemoglobin; PT, prothrombin time; aPTT, activated partial thromboplastin time; ESD, endoscopic submucosal dissection; PPI, proton pump inhibitor; U, upper; M, middle; L, lower; AW, anterior wall; PW, posterior wall; LC, lesser curvature; GC, greater curvature; LGD, low grade dysplasia; HGD, high grade dysplasia; E, epithelium; LP, lamina propria; MM, muscularis mucosae; S, submucosa; *H. pylori, Helicobacter pylori.*

Unpaired t-test;

Fisher exact test;

Chi-square test.
